Goldman Sachs’s RAPT Therapeutics RAPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-254,053
| Closed | -$8.6M | – | 6896 |
|
|
2025
Q4 | $8.6M | Buy |
254,053
+192,477
| +313% | +$5.98M | ﹤0.01% | 3245 |
|
|
2025
Q3 | $1.59M | Buy |
61,576
+39,310
| +177% | +$514K | ﹤0.01% | 4678 |
|
|
2025
Q2 | $178K | Sell |
22,266
-20,508
| -48% | -$156K | ﹤0.01% | 5693 |
|
|
2025
Q1 | $417K | Sell |
42,774
-18,095
| -30% | -$178K | ﹤0.01% | 5292 |
|
|
2024
Q4 | $769K | Buy |
60,869
+11,150
| +22% | +$142K | ﹤0.01% | 5002 |
|
|
2024
Q3 | $799K | Buy |
49,719
+2,995
| +6% | +$60.6K | ﹤0.01% | 4787 |
|
|
2024
Q2 | $1.14M | Buy |
46,724
+23,446
| +101% | +$1.08M | ﹤0.01% | 4347 |
|
|
2024
Q1 | $1.67M | Sell |
23,278
-1,257
| -5% | -$175K | ﹤0.01% | 3989 |
|
|
2023
Q4 | $4.88M | Buy |
24,535
+2,289
| +10% | +$283K | ﹤0.01% | 3181 |
|
|
2023
Q3 | $2.96M | Sell |
22,246
-1,214
| -5% | -$198K | ﹤0.01% | 3447 |
|
|
2023
Q2 | $3.51M | Buy |
23,460
+1,702
| +8% | +$265K | ﹤0.01% | 3415 |
|
|
2023
Q1 | $3.19M | Sell |
21,758
-2,977
| -12% | -$602K | ﹤0.01% | 3472 |
|
|
2022
Q4 | $3.92M | Buy |
24,735
+4,004
| +19% | +$641K | ﹤0.01% | 3392 |
|
|
2022
Q3 | $3.99M | Buy |
20,731
+17,236
| +493% | +$3.26M | ﹤0.01% | 3335 |
|
|
2022
Q2 | $511K | Sell |
3,495
-2,830
| -45% | -$377K | ﹤0.01% | 5066 |
|
|
2022
Q1 | $1.11M | Buy |
6,325
+1,792
| +40% | +$338K | ﹤0.01% | 4735 |
|
|
2021
Q4 | $1.33M | Buy |
4,533
+588
| +15% | +$157K | ﹤0.01% | 4605 |
|
|
2021
Q3 | $980K | Sell |
3,945
-6,160
| -61% | -$1.63M | ﹤0.01% | 4762 |
|
|
2021
Q2 | $2.57M | Buy |
10,105
+8,824
| +689% | +$1.65M | ﹤0.01% | 3970 |
|
|
2021
Q1 | $227K | Sell |
1,281
-783
| -38% | -$129K | ﹤0.01% | 5584 |
|
|
2020
Q4 | $326K | Buy |
+2,064
| New | +$449K | ﹤0.01% | 4847 |
|
|
2020
Q3 | – | Sell |
-11,043
| Closed | -$2.56M | – | 5511 |
|
|
2020
Q2 | $2.56M | Buy |
+11,043
| New | +$1.71M | ﹤0.01% | 3281 |
|
Goldman Sachs's RAPT Position: Q1 2026 in Review
Goldman Sachs sold out of RAPT Therapeutics (RAPT) in Q1 2026, closing a stake of 254,053 shares — an estimated $8.6M sold.
Goldman Sachs first reported a position in RAPT in Q2 2020 and held it in 22 quarters. The position peaked at $8.6M in Q4 2025. 0 funds tracked by Wall St. Rank hold RAPT as of Q1 2026.
- Goldman Sachs reported no remaining RAPT Therapeutics position as of Q1 2026 after selling out during the quarter.
- Goldman Sachs sold 254,053 RAPT Therapeutics shares in Q1 2026, an estimated $8.6M.
- Goldman Sachs first reported a position in RAPT Therapeutics in Q2 2020 and held it in 22 quarters.
- Goldman Sachs's RAPT Therapeutics position peaked at $8.6M in Q4 2025.
- 0 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2026.
Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.